Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: A systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management of polymyalgia rheumatica

Annals of the Rheumatic Diseases

Volumn 74, Issue 10, 2015, Pages 1808-1817

  Dejaco, Christian ^a,b   Singh, Yogesh P ^b   Perel, Pablo ^c   Hutchings, Andrew ^c   Camellino, Dario ^d   Mackie, Sarah ^e   Matteson, Eric L ^f   Dasgupta, Bhaskar ^b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b SOUTHEND UNIVERSITY HOSPITAL   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d UNIVERSITY OF GENOA   (Italy)

^e UNIVERSITY OF LEEDS   (United Kingdom)

^f Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; ETANERCEPT; GLUCOCORTICOID; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

AGE DISTRIBUTION; ARTHRITIS; DISEASE ACTIVITY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FRAGILITY FRACTURE; HUMAN; LONG TERM CARE; LOW DRUG DOSE; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; REMISSION; REVIEW; RHEUMATIC POLYMYALGIA; RISK FACTOR; SEX DIFFERENCE; SHORT COURSE THERAPY; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; DRUG ADMINISTRATION; EVIDENCE BASED MEDICINE; INTRAMUSCULAR DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; POLYMYALGIA RHEUMATICA; PRACTICE GUIDELINE; PROCEDURES;

ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; GLUCOCORTICOIDS; HUMANS; INJECTIONS, INTRAMUSCULAR; POLYMYALGIA RHEUMATICA; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RISK FACTORS;

EID: 84942940050     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-207578     Document Type: Review

References (73)

1. Helliwell T, Hider SL, Mallen CD. Polymyalgia rheumatica: diagnosis, prescribing, and monitoring in general practice. Br J Gen Pract 2013;63:e361-6.
2. Dasgupta B, Borg FA, Hassan N, et al. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford) 2010;49:186-90.
3. Schmidt WA, Gromnica Ihle E. Polymyalgia rheumatica und Riesenzellarteriitis (Arteriitis temporalis). In: Busse O, Fleig W, Mayet W, et al., eds. Rationelle Diagnostik und Therapie in der Inneren Medizin: Leitlinien-basierte Empfehlungen für die Praxis. Elsevier Inc, 2011; Chapter 5.2.
4. Hutchings A, Hollywood J, Lamping DL, et al. Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica. Arthritis Rheum 2007;57:803-9.
5. 4a Dejaco C, Singh YP, Perel P, et al. 2015 Recommendations for Management of Polymyalgia Rheumatica: An European League Against Rheumatism and American College of Rheumatology Collaborative Initiative. Ann Rheum Dis 2015;74:1799-1807.
6. 4b Dejaco C, Singh YP, Perel P, et al. 2015 Recommendations for Management of Polymyalgia Rheumatica: An European League Against Rheumatism and American College of Rheumatology Collaborative Initiative. Arthritis Rheumatol 2015. (in press).
7. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011;64:383-94.
8. Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64:401-6.
9. Group GW. GRADE homepage. http://www.gradeworkinggroup.org/index.htm
10. Hayden JA, Côté P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 2006;144:427-37.
11. Catoggio W, Soriano ER, Imamura PM. Treatment of polymyalgia rheumatica: lower initial dose. Br J Rheumatol 1991;30:393-5.
12. Caporali R, Cimmino MA, Ferraccioli G, et al. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2004;141:493-500.
13. Cimmino MA, Salvarani C, Macchioni P, et al. Long-term follow-up of polymyalgia rheumatica patients treated with methotrexate and steroids. Clin Exp Rheumatol 2008;26:395-400.
14. Delecoeuillerie G, Joly P, Cohen de Lara A, et al. Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients). Ann Rheum Dis 1988;47:733-9.
15. Dasgupta B, Dolan AL, Panayi GS, et al. An initially double-blind controlled 96 week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica. Br J Rheumatol 1998;37:189-95.
16. Dolan AL, Moniz C, Dasgupta B, et al. Effects of inflammation and treatment on bone turnover and bone mass in polymyalgia rheumatica. Arthritis Rheum 1997;40:2022-9.
17. Ferraccioli G, Salaffi F, De Vita S, et al. Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study. J Rheumatol 1996;23:624-8.
18. Fu HZ. [Clinical observation on effect of modified Yanghe Decoction combined with glycocorticoid for treatment of polymyalgia rheumatica]. Zhongguo Zhong Xi Yi Jie He Za Zhi 2007;27:894-7.
19. Gabriel SE, Sunku J, Salvarani C, et al. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum 1997;40:1873-8.
20. Kanemaru K, Nagura H, Ooyama T, et al. [Report of 6 cases with polymyalgia rheumatica and a review of the literature]. Nihon Ronen Igakkai Zasshi 1986;23:469-76.
21. Kreiner F, Galbo H. Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial. Arthritis Res Ther 2010;12:R176.
22. Kremers HM, Reinalda MS, Crowson CS, et al. Relapse in a population based cohort of patients with polymyalgia rheumatica. J Rheumatol 2005;32:65-73.
23. Maradit Kremers H, Reinalda MS, Crowson CS, et al. Glucocorticoids and cardiovascular and cerebrovascular events in polymyalgia rheumatica. Arthritis Rheum 2007;57:279-86.
24. Kyle V, Hazleman BL. Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months. Ann Rheum Dis 1989;48:658-61.
25. Kyle V, Hazleman BL. Treatment of polymyalgia rheumatica and giant cell arteritis. II. Relation between steroid dose and steroid associated side effects. Ann Rheum Dis 1989;48:662-6.
26. Lee JH, Choi ST, Kim JS, et al. Clinical characteristics and prognostic factors for relapse in patients with polymyalgia rheumatica (PMR). Rheumatol Int 2013;33:1475-80.
27. Mackie SL, Hensor EM, Haugeberg G, et al. Can the prognosis of polymyalgia rheumatica be predicted at disease onset? Results from a 5-year prospective study. Rheumatology (Oxford) 2010;49:716-22.
28. Myklebust G, Gran JT. Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis. A prospective two-year study in 273 patients. Scand J Rheumatol 2001;30:260-7.
29. Nazarinia AM, Moghimi J, Toussi J. Efficacy of methotrexate in patients with polymyalgia rheumatica. Koomesh 2013;14:265-70.
30. Salvarani C, Macchioni P, Manzini C, et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann Intern Med 2007;146:631-9.
31. Van der Veen MJ, Dinant HJ, van Booma-Frankfort C, et al. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis 1996;55:218-23.
32. Wang B, Zhang B, Wang H. Clinical observation about 18 cases of polymyalgia rheumatica by using Biqi capsule. China J Tradit Chin Med Pharm 2009;24:596-8.
33. Ayoub WT, Franklin CM, Torretti D. Polymyalgia rheumatica. Duration of therapy and long-term outcome. Am J Med 1985;79:309-15.
34. Barraclough K, Liddell WG, du Toit J, et al. Polymyalgia rheumatica in primary care: a cohort study of the diagnostic criteria and outcome. Fam Pract 2008;25:328-33.
35. Cantini F, Salvarani C, Olivieri I, et al. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin Arthritis Rheum 2000;30:17-24.
36. Caplanne D, Le Parc JM, Alexandre JA. Interleukin-6 in clinical relapses of polymyalgia rheumatica and giant cell arteritis. Ann Rheum Dis 1996;55:403-4.
37. Ceccato F, Roverano SG, Papasidero S, et al. Peripheral musculoskeletal manifestations in polymyalgia rheumatica. JCR J Clin Rheumatol 2006;12:167-71.
38. Cimmino MA, Moggiana G, Montecucco C, et al. Long term treatment of polymyalgia rheumatica with deflazacort. Ann Rheum Dis 1994;53:331-3.
39. Cimmino MA, Parodi M, Caporali R, et al. Is the course of steroid-treated polymyalgia rheumatica more severe in women? Ann N Y Acad Sci 2006;1069:315-21.
40. Cimmino MA, Parodi M, Montecucco C, et al. The correct prednisone starting dose in polymyalgia rheumatica is related to body weight but not to disease severity. BMC Musculoskelet Disord 2011;12:94.
41. Do-Nguyen D, Inderjeeth C, Edelman J, et al. Retrospective analysis of the clinical course of patients treated for polymyalgia. Open Access Rheumatol Res Rev 2013;5:33-41.
42. Gonzalez-Gay MA, Rodriguez-Valverde V, Blanco R, et al. Polymyalgia rheumatica without significantly increased erythrocyte sedimentation rate. A more benign syndrome. Arch Intern Med 1997;157:317-20.
43. González-Gay MA, García-Porrúa C, Vázquez-Caruncho M, et al. The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study. J Rheumatol 1999;26:1326-32.
44. Gran JT, Myklebust G, Wilsgaard T, et al. Survival in polymyalgia rheumatica and temporal arteritis: a study of 398 cases and matched population controls. Rheumatology (Oxford) 2001;40:1238-42.
45. Helfgott SM, Kieval RI. Polymyalgia rheumatica in patients with a normal erythrocyte sedimentation rate. Arthritis Rheum 1996;39:304-7.
46. Kanik KS, Bridgeford PH, Germain BF, et al. Polymyalgia rheumatica with a low erythrocyte sedimentation rate: comparison of 10 cases with 10 cases with high erythrocyte sedimentation rate. J Clin Rheumatol 1997;3:319-23.
47. Kim HA, Lee J, Ha YJ, et al. Induction of remission is difficult due to frequent relapse during tapering steroids in Korean patients with polymyalgia rheumatica. J Korean Med Sci 2012;27:22-6.
48. Kimura M, Tokuda Y, Oshiawa H, et al. Clinical characteristics of patients with remitting seronegative symmetrical synovitis with pitting edema compared to patients with pure polymyalgia rheumatica. J Rheumatol 2012;39:148-53.
49. Kremers HM, Reinalda MS, Crowson CS, et al. Use of physician services in a population-based cohort of patients with polymyalgia rheumatica over the course of their disease. Arthritis Rheum 2005;53:395-403.
50. Larrosa M, Gratacos J, Sala M. Polymyalgia rheumatica with low erythrocyte sedimentation rate at diagnosis. J Rheumatol 2000;27:1815-16.
51. Mazzantini M, Torre C, Miccoli M, et al. Adverse events during longterm low-dose glucocorticoid treatment of polymyalgia rheumatica: a retrospective study. J Rheumatol 2012;39:552-7.
52. Meyerhoff J. Evaluating an alternative oral regimen for the treatment of polymyalgia rheumatica. J Clin Rheumatol 2000;6:61.
53. Nagaoka S, Ohno M, Ohno S, et al. Long-term outcome for patients with polymyalgia rheumatica. Rinshou Ryumachi 2000;12:348-52.
54. Paulsen S. [Polymyalgia rheumatica. Long term treatment with steroids]. Ugeskr Laeger 1971;133:944-5.
55. Prickarts M, Lagro-Janssen T, Lagro-Janssen ALM. Polymyalgia rheumatica in four general practices. [Dutch] Polymyalgia rheumatica in vier huisartspraktijken. Huisarts Wet 1999;42:597-601.
56. Proven A, Gabriel SE, O'Fallon WM, et al. Polymyalgia rheumatica with low erythrocyte sedimentation rate at diagnosis. J Rheumatol 1999;26:1333-7.
57. Salvarani C, Cantini F, Macchioni P, et al. Distal musculoskeletal manifestations in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum 1998;41:1221-6.
58. Salvarani C, Boiardi L, Mantovani V, et al. HLA-DRB1 alleles associated with polymyalgia rheumatica in northern Italy: correlation with disease severity. Ann Rheum Dis 1999;58:303-8.
59. Salvarani C, Cantini F, Niccoli L, et al. Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum 2005;53:33-8.
60. Schaufelberger C, Bengtsson BA, Andersson R. Epidemiology and mortality in 220 patients with polymyalgia rheumatica. Br J Rheumatol 1995;34:261-4.
61. Schreiber S, Buyse M. The CRP initial response to treatment as prognostic factor in patients with polymyalgia rheumatica. Clin Rheumatol 1995;14:315-18.
62. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
63. Lopez-Olivo MA, Siddhanamatha HR, Shea B, et al. Methotrexate for treating rheumatoid arthritis. Cochrane database Syst Rev 2014;6:CD000957.
64. Díaz-Borjón A. Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis. Drugs Aging 2009;26:273-93.
65. Salvarani C, Cantini F, Niccoli L, et al. Treatment of refractory polymyalgia rheumatica with infliximab: a pilot study. J Rheumatol 2003;30:760-3.
66. Migliore A, Massafra U, Carloni E, et al. TNF-alpha blockade induce clinical remission in patients affected by polymyalgia rheumatica associated to diabetes mellitus and/or osteoporosis: a seven cases report. Eur Rev Med Pharmacol Sci 2005;9:373-8.
67. Corrao S, Pistone G, Scaglione R, et al. Fast recovery with etanercept in patients affected by polymyalgia rheumatica and decompensated diabetes: a case-series study. Clin Rheumatol 2009;28:89-92.
68. Catanoso MG, Macchioni P, Boiardi L, et al. Treatment of refractory polymyalgia rheumatica with etanercept: an open pilot study. Arthritis Rheum 2007;57:1514-19.
69. Al Rashidi A, Hegazi MO, Mohammad SA, et al. Effective control of polymyalgia rheumatica with tocilizumab. J Clin Rheumatol 2013;19:400-1.
70. Macchioni P, Boiardi L, Catanoso M, et al. Tocilizumab for polymyalgia rheumatica: report of two cases and review of the literature. Semin Arthritis Rheum 2013;43:113-18.
71. Hernandez-Rodriguez J, Cid MC, Lopez-Soto A, et al. Treatment of polymyalgia rheumatica: a systematic review. Arch Intern Med 2009;169:1839-50.
72. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011.
73. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.